Small Cell Lung Cancer (SCLC)

Results showed of the phase 3 ADRIATIC study found that treatment with durvalumab elicited similar radiation pneumonitis incidences vs placebo for LS-SCLC.

James Ninia, MD, discussed a phase 2/3 trial seeking to answer whether complete consolidation offers more benefit than incomplete consolidation in SCLC.

Overall survival benefit was significant with complete vs incomplete consolidation therapy, but lost significance when stratified by disease burden.

James Ninia, MD, discussed treatment options for patients with extensive-stage small cell lung cancer undergoing metastasis-directed radiotherapy.

Data show that twice-daily radiotherapy may confer improved survival vs once-daily radiation in patients with limited-stage small cell lung cancer.

BMS-986012 in combination with nivolumab/chemotherapy showed numerical PFS improvements in those with and without brain metastases at baseline.

The magnitude of benefit with durvalumab was particularly consistent within prophylactic cranial irradiation and radiation subgroups in the ADRIATIC trial.

Supporting data for the designation comes from the ARTEMIS-001 trial evaluating preliminary safety and antitumor activity of GSK’227 in solid tumors.

Data from the phase 3 ADRIATIC trial support the supplemental biologics license application for durvalumab in this limited-stage SCLC population.

The overall survival data in the phase 3 KeyVibe-008 trial met the prespecified futility criteria.

The Oncology Brothers and Eric Singhi, MD, provide clinical insights on the treatment of patients with small cell lung cancer with driver mutations.

Eric Singhi, MD, joins the Oncology Brothers to discuss adverse event management practices for patients with small cell lung cancer.

Medical oncologists provide comprehensive insights on treatment practices for patients with extended-stage small cell lung cancer.

Following recent data from the ADRIATIC study, the Oncology Brothers and Eric Singhi, MD, discuss the role of prophylactic cranial irradiation (PCI) in patients with small cell lung cancer.

Eric Singhi, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss the treatment algorithm for patients with limited-stage small cell lung cancer (SCLC), highlighting the ADRIATIC study.

The phase 2 DELLphi-301 trial showed durable response rates when tarlatamab was used to treat extensive-stage small cell lung cancer.

Treatment with SNB-101 previously demonstrated tolerability among patients with solid tumors in a phase 1 trial.

Treatment with durvalumab raises no new safety signals among patients with limited-stage small cell lung cancer in the phase 3 ADRIATIC trial.

Practices are on the cusp of better understanding small cell lung cancer that in turn can help to advance treatment strategies for patients, says Gregory Peter Kalemkerian, MD.

The use of novel agents like tarlatamab may be “interesting” among patients with small cell lung cancer in the relapsed setting, says Gregory Peter Kalemkerian, MD.

Prophylactic cranial irradiation may not be worthwhile for treating patients with extensive-stage small cell lung cancer based on conflicting data, according to Gregory Peter Kalemkerian, MD.

FDA-approved immunotherapy options such as atezolizumab and durvalumab have produced substantial benefits in certain groups of patients with extensive-stage small cell lung cancer, says Gregory Peter Kalemkerian, MD.

A post hoc analysis of lurbinectedin showed an improvement in the overall response rate compared with topotecan for patients with small cell lung cancer.

The FDA sets a Prescription Drug User Fee Act date of June 12, 2024, for tarlatamab as a therapy for patients with advanced small cell lung cancer.

Investigators are assessing BI 764532 in extensive-stage small cell lung cancer and other neuroendocrine carcinoma as part of the phase 2 DAREON-5 study.